Intensive voice treatment in Parkinson's disease: Lee Silverman Voice Treatment

Expert Review of Neurotherapeutics

Volumn 11, Issue 6, 2011, Pages 815-830

  Sapir, Shimon ^a   Ramig, Lorraine O ^b,c   Fox, Cynthia M ^c  

^a UNIVERSITY OF HAIFA   (Israel)

^b UNIVERSITY OF COLORADO   (United States)

^c University of Arizona   (United States)

Author keywords

Lee Silverman Voice Treatment; LSVT; neural plasticity; Parkinson's disease; speech and voice disorders; swallowing disorders

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA;

AKINESIA; AMPLITUDE MODULATION; BEHAVIOR THERAPY; BRADYKINESIA; BRAIN DEPTH STIMULATION; CLINICAL EFFECTIVENESS; DYSARTHRIA; DYSPHONIA; ELECTROMYOGRAPHY; HUMAN; HYPOKINETIC DYSARTHRIA; LARYNX MUSCLE; LEE SILVERMAN VOICE TREATMENT; LOUDNESS; MEDICAL RESEARCH; MUSCLE RIGIDITY; NEUROPSYCHOLOGY; NONHUMAN; PALLIDOTOMY; PARKINSON DISEASE; REVIEW; SENSORY SYSTEM; SPEECH DISORDER; SPEECH THERAPY; STUTTERING; THALAMOTOMY; THERAPY EFFECT; THORAX WALL; TREMOR; VITAL CAPACITY; VOICE CHANGE;

HUMANS; PARKINSON DISEASE; SPEECH DISORDERS; SPEECH THERAPY; VOICE; VOICE DISORDERS; VOICE TRAINING;

EID: 79958293781     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.11.43     Document Type: Review

References (176)

1. Fisher BE, Wu AD, Salem GJ, et al. The effect of exercise training in improving motor performance and corticomotor excitability in people with early Parkinson's disease. Arch. Phys. Med. Rehabil. 89(7), 1221-1229 (2008). (Pubitemid 351884995)
2. Hirsch MA, Farley BG. Exercise and neuroplasticity in persons living with Parkinson's disease. Eur. J. Phys. Rehabil. Med. 45, 215-229 (2009).
3. Petzinger G, Fisher B, Van Leeuwen J-E, et al. Enhancing neuroplasticity in the basal ganglia: the role of exercise in Parkinson's disease. Mov. Disord. 25, S141-S145 (2010).
4. Kleim JA, Jones TA. Principles of experience-dependent neural plasticity: implications for rehabilitation after brain damage. J. Speech Lang. Hear. Res. 51, S225-S239 (2008). (Pubitemid 351206588)
5. Kleim J, Jones T, Schallert T. Motor enrichment and the induction of plasticity before or after brain injury. Neurochem. Res. 11, 1757-1769 (2003). (Pubitemid 37296217)
6. Zigmond MJ, Cameron JL, Leak RK, et al. Triggering endogenous neuroprotective processes through exercise in models of dopamine deficiency. Parkinsonism Relat. Disord. 1553, 542-545 (2009).
7. Keus S, Munneke M, Nijkrake M, Kwakkel G, Bloem B. Physical therapy in Parkinson's disease: evolution and future challenges. Mov. Disord. 24, 1-14 (2009).
8. de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol. 5(6), 525-535 (2006).
9. Ho A, Iansek R, Marigliani C, Bradshaw JL, Gates S. Speech impairment in a large sample of people with Parkinson's disease. Behav. Neurol. 11, 131-137 (1998). (Pubitemid 29537551)
10. Darley F, Aronson A, Brown J. Hypokinetic Dysarthria. In: Motor Speech Disorders. Saunders, PA, USA (1975).
11. Ho A, Iansek R, Bradshaw JL. Motor instability in Parkinsonian speech intensity. Neuropsychiatry Neuropsychol. Behav. Neurol. 14, 109-116 (2001). (Pubitemid 32549935)
12. Baumgartner C, Sapir S, Ramig LO. Voice quality changes following phonatory-respiratory effort treatment (LSVT®) versus respiratory effort treatment for people with Parkinson disease. J. Voice 14, 105-114 (2001). (Pubitemid 32231496)
13. Adams S. Hypokinetic dysarthria in Parkinson's disease. In: Clinical Management of Sensorimotor Speech Disorders. McNeil MR (Ed.). Thieme, NY, USA (1997).
14. Forrest K, Weismer G, Turner G. Kinematic, acoustic and perceptual analysis of connected speech produced by Parkinsonian and normal geriatric adults. J. Acoust. Soc. Am. 85, 2608-2622 (1989). (Pubitemid 19160388)
15. Sapir S, Spielman, J, Ramig LO, Story BS, Fox C. Effects of intensive voice treatment (the Lee Silverman Voice Treatment [LSVT]) on vowel articulation in dysarthric individuals with idiopathic Parkinson disease: acoustic and perceptual findings. J. Speech Lang. Hear. Res. 50, 899-912 (2007). (Pubitemid 350058568)
16. Sapir S, Pawlas AA, Ramig LO, et al. Voice and speech abnormalities in Parkinson disease: relation to severity of motor impairment, duration of disease, medication, depression, gender, and age. J. Med. Speech Lang. Pathol. 9, 213-226 (2001). (Pubitemid 33685879)
17. Benke T, Hohenstein C, Poewe W, Butterworth B. Repetitive speech phenomena in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry. 69, 319-324 (2000).
18. McClean M. Neuromotor aspects of speech production and dysarthria. In: Clinical Management of Dysarthric Speakers. Yorkston KM, Beukelman DR, Bell KR (Eds.). A College-Hill Publication, Little, Brown and Co., CA, USA, 19-58 (1988).
19. Perez K, Ramig LO, Smith M, Dromey C. The Parkinson larynx: tremor and videostroboscopic findings. J. Voice 10, 354-361 (1996). (Pubitemid 26394224)
20. Smith M, Ramig LO, Dromey C, Perez K, Samandari R. Intensive voice treatment in Parkinson's disease: laryngostroboscopic findings. J. Voice 9, 453-459 (1995).
21. Solomon N, Hixon TJ. Speech breathing in Parkinson's disease. J. Speech Hear. Res. 36, 294-310 (1993).
22. Baker K, Ramig LO, Luschei E, Smith M. Thyroarytenoid muscle activity associated with hypophonia in Parkinson disease and aging. Neurology 51, 1592-1598 (1998). (Pubitemid 28565237)
23. Gallena S, Smith PJ, Zeffiro T, Ludlow CL. Effects of levodopa on laryngeal muscle activity for voice onset and offset in Parkinson disease. J. Speech Hear. Res. 44, 1284-1299 (2001). (Pubitemid 34008277)
24. Vincken W, Gauthier SG, Dollfuss RE, Hanson RE, Parauay CM, Cosio MG. Involvement of upper-airway muscles in extrapyramidal disorders, a cause of airflow limitation. N. Engl. J. Med. 7, 438-442 (1984). (Pubitemid 14058255)
25. Ackermann H, Ziegler W. Articulatory deficits in parkinsonian dysarthria. J. Neurol. Neurosurg. Psychiatry. 54, 1093-1098 (1991).
26. Ackermann H, Konczak J, Hertrich I. The temporal control of repetitive articulatory movements in Parkinson's disease. Brain Lang. 56, 312-319 (1997). (Pubitemid 27184985)
27. Caligiuri M, Abbs JH. Response properties of the perioral reflex in Parkinson's disease. Exp. Neurol. 98, 563-572 (1987). (Pubitemid 18026592)
28. Hirose H. Pathophysiology of motor speech disorders (dysarthria). Folia Phoniat. Basel 38, 61-88 (1986).
29. Leanderson R, Persson A, Ohman S. Electromyographic studies of the function of the facial muscles in dysarthria. Acta Otolaryngol. 263, 89-94 (1970).
30. Leanderson R, Meyerson B, Persson A. Lip muscle function in Parkinsonian dysarthria. Acta Otolaryngol. 74, 350-357 (1972).
31. Radad K, Gille G, Rausch W. Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson's disease. Pharmacologic Rep. 57, 701-712 (2005).
32. Goberman A. Correlation between acoustic speech characteristics and non-speech motor performance in Parkinson disease. Med. Sci. Monit. 11, CR109-CR116 (2005). (Pubitemid 40445982)
33. Trail M, Fox C, Ramig LO, Sapir S, Howard J, Lai EC. Speech treatment for Parkinson's disease. NeuroRehabilitation 20, 205-221 (2005).
34. De Letter M, Santens P, Van Borsel J. The effects of levodopa on word intelligibility in Parkinson's disease. J. Commun. Disord. 38, 187-196 (2005).
35. Goberman A, Coelho C, Robb M. Phonatory characteristics of Parkinsonian speech before and after morning medication: the ON and OFF states. J. Commun. Disord. 35, 217-239 (2002). (Pubitemid 34665409)
36. Jiang J, Lin E, Wang J, Hanson DG. Glottographic measures before and after levodopa treatment in Parkinson's disease. Laryngoscope 109, 1287-1294 (1999). (Pubitemid 29379441)
37. Sanabria J, Ruiz PG, Gutierrez R, et al. The effect of levodopa on vocal function in Parkinson's disease. Clin. Neuropharmacol. 24, 99-102 (2001). (Pubitemid 32294685)
38. Cahill L, Murdoch BE, Theodoros DG, Triggs EJ, Charles BG, Yao AA. Effect of oral levodopa treatment on articulatory function in Parkinson's disease: preliminary results. Motor Control 2, 161-172 (1998).
39. Kompoliti K, Wang QE, Goetz CG, Leurgans S, Raman R. Effects of central dopaminergic stimulation by apomorphine on speech in Parkinson's disease. Neurology 54, 458-462 (2000). (Pubitemid 30078084)
40. Larson K, Ramig LO, Scherer RC. Acoustic and glottographic voice analysis during drug-related fluctuations in Parkinson's disease. J. Med. Speech Lang. Pathol. 2, 211-226 (1994).
41. Skodda S, Visser W, Schlegel U. Short- and long-term dopaminergic effects on dysarthria in early Parkinson's disease. J. Neural Transm. 117, 197-205 (2010).
42. Spencer K, Morgan K, Blond E. Dopaminegic medication effects on the speech of individuals with Parkinson's disease. J. Med. Speech Lang. Pathol. 17, 125-144 (2009).
43. Biary N, Pimental PA, Langenberg PW. A double-blind trial of clonazepan in the treatment of parkinsonian dysarthria. Neurology 38, 255-258 (1988). (Pubitemid 18036848)
44. Ghika J, Ghika-Schmid F, Fankhauser H, et al. Bilateral contemporaneous posteroventral pallidotomy for the treatment of Parkinson's disease: neuropsychological and neurological side effects, report of four cases and review of the literature. J. Neurosurg. 91, 313-321 (1999).
45. Krack P, Batir A, VanBiercom N, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N. Engl. J. Med. 345, 1925-1934 (2003). (Pubitemid 37409709)
46. Gentil M, Garcia-Ruiz P, Pollak P, Benabid A-L. Effect of stimulation of the subthalamic nucleus on oral control of patients with Parkinsonism. J. Neurol. Neurosurg. Psychiatry 67, 329-333 (1999). (Pubitemid 29392592)
47. Gentil M, Garcia-Ruiz P, Pollak P, Benabid A-L. Effect of bilateral deep-brain stimulation on oral control of patients with Parkinsonism. Eur. Neurol. 44, 147-152 (2000).
48. Gentil M, Chauvin P, Pinto S, Pollak P, Benabid A-L. Effect of bilateral stimulation of the subthalamic nucleus on Parkinsonian voice. Brain Lang. 78, 233-240 (2001). (Pubitemid 32758107)
49. Gentil M, Pinto S, Pollak P, Benabid A-L. Effect of bilateral stimulation of the subthalamic nucleus on Parkinsonian dysarthria. Brain Lang. 85, 190-196 (2003). (Pubitemid 36542853)
50. Pinto S, Gentil M, Krack P, et al. Changes induced by levodopa and subthalamic nucleus stimulation on Parkinsonian speech. Mov. Disord. 20 (11), 1507-1515 (2005). (Pubitemid 43072662)
51. Tripoliti E, Zrino L, Martinez-Torres I, et al. Effects of contact location and voltage amplitude on speech and movement in bilateral subthalamic nucleus deep brain stimulation. Mov. Disord. 23, 2377-2383 (2008).
52. Romito LM, Albanese A. Dopaminergic therapy and subthalamic stimulation in Parkinson's disease: a review of 5-year reports. J Neurol. 257(Suppl. 2), S298-S304 (2010).
53. Ramig LO, Fox C, Sapir S. Speech treatment for Parkinson's disease. Expert Rev. Neurother. 8, 297-309 (2008).
54. Sapir S, Ramig L, Fox C. Speech and swallowing disorders in Parkinson's disease. Curr. Opin. Otolaryngol. Head Neck Surg. 16, 205-210 (2008). (Pubitemid 351677652)
55. Törnqvist AL, Schalén L, Rehncrona S. Effects of different electrical parameter settings on the intelligibility of speech in patients with Parkinson's disease treated with subthalamic deep brain stimulation. Mov. Disord. 20, 416-423 (2005). (Pubitemid 40779016)
56. Astrom M, Tripoliti E, Hariz MI, et al. Patient-specific model-based investigation of speech intelligibility and movement during deep brain stimulation. Stereotach. Funct. Neurosurg. 88, 224-233 (2010).
57. Tommasi G, Krack P, Fraix V, et al. Pyramidal tract side effects induced by deep brain stimulation of the subthalamic nucleus. J. Neurol. Neurosurg. Psychiatry 79, 813-819 (2008). (Pubitemid 351914730)
58. Rosen K, Kent RD, Duffy JR. Task-based profile of vocal intensity decline in Parkinson's disease. Folia Phoniat. Logoped. 57, 28-37 (2005).
59. Caligiuri M. The influence of speaking rate on articulatory hypokinesia in Parkinsonian dysarthria. Brain Lang. 36, 493-502 (1989). (Pubitemid 19105260)
60. Liss JM, Spitzer SM, Caviness JN, Adler C. The effects of familiarization on intelligibility and lexical segmentation in hypokinetic and ataxic dysarthria. J. Acoust. Soc. Am. 112, 3022-3030 (2002). (Pubitemid 37033879)
61. Sapir S, Ramig LO, Spielman JL, Fox C. Formant centralization ratio: a proposal for a new acoustic measure of dysarthric speech. J. Speech Lang. Hear. Res. 53, 114-125 (2010).
62. Skodda S, Visser W, Schlegel U. Vowel articulation in Parkinson's disease. J. Voice DOI: 10.1016/j.jvoice.2010.01.009 (2010) (Epub ahead of print).
63. Bartels AL, Leenders KL. Parkinson's disease: the syndrome, the pathogenesis and pathophysiology. Cortex 45, 915-921 (2009).
64. Demirci M, Grill S, McShane L, Hallet M. Impairment of kinesthesia in Parkinson's disease. Neurology 45, A218 (1995).
65. Desmurget M, Grafton ST, Vindras P, Gréa H, Turner RS. Basal ganglia network mediates the control of movement amplitude. Exp. Brain Res. 153, 197-209 (2003). (Pubitemid 37445312)
66. Desmurget M, Grafton ST, Vindras P, Gréa H, Turner RS. The basal ganglia network mediates the planning of movement amplitude. Eur. J. Neurosci. 19, 2871-2880 (2004). (Pubitemid 38746403)
67. Hallet M. Sensorimotor integration and mysterious sensory phenomena in movement disorders. In: Motor Control. Hallet M (Ed.) American Academy of Neurology, MN, USA (1997).
68. Morris M, Iansek R, Matyas T, Summers J. Abnormalities in the stride length-cadence relation in Parkinsonian gait. Mov. Disord. 13, 61-69 (1998). (Pubitemid 28029854)
69. Demirci M, Grill S, McShane L, Hallett M. A mismatch between kinesthetic and visual perception in Parkinson's disease. Ann. Neurol. 41, 781-788 (1997). (Pubitemid 27249183)
70. Jobst EE, Melnick ME, Byl NN, Dowling GA, Aminoff MJ. Sensory perception in Parkinson's disease. Arch. Neurol. 54, 450-454 (1997).
71. Klockgether T, Borutta M, Rapp H, Spieder S, Dichgans J. A defect of kinesthesia in Parkinson's disease. Brain 120, 460-465 (1997).
72. Schneider S, Diamond SG, Markham CH. Deficits in orofacial sensorimotor function in Parkinson's disease. Ann. Neurol. 19, 275-282 (1986). (Pubitemid 16111077)
73. Diamond SG, Schneider JS, Markham CH. Oral sensorimotor defects in people with Parkinson's disease. Adv. Neurol. 45, 335-338 (1987).
74. Rickards C, Cody FW. Proprioceptive control of wrist movements in Parkinson's disease. Brain 120, 977-990 (1997).
75. Schneider JS, Lidsky TI. Basal Ganglia and Behavior: Sensory Aspects of Motor Functioning. Hans Huber, Toronto, Canada (1987).
76. Graber S, Hertrich I, Daum I, Spieker S, Ackermann H. Speech perception deficits in Parkinson's disease: underestimation of time intervals compromises identification of durational phonetic contrasts. Brain Lang. 82, 65-74 (2002).
77. Ho AK, Bradshaw JL, Iansek R, Alfredson R. Speech volume regulation in Parkinson's disease: Effects of implicit cues and explicit instructions. Neuropsychologia 37. 1453-1460 (1999).
78. Ho AK, Iansek R, Bradshaw JL. Regulations of parkinsonian speech volume: the effect of interlocuter distance. J. Neurol. Neurosurg. Psychiatry 67, 199-202 (1999). (Pubitemid 29326952)
79. Ho A, Bradshaw JL, Iansek T. Volume perception in Parkinsonian speech. Mov. Disord. 15, 1125-1131 (2000).
80. Solomon NP, Robin DA, Lorell DM, Rodnitzky RL, Luschei ES. Tongue function testing in Parkinson's Disease: indicators of fatigue. In Motor Speech Disorders: Advances in Assessment and Treatment. Till JA, Yorkston KM, Beukelman R (Eds). Paul H Brooks, MD, USA, 147-160 (1994).
81. Hammer MJ. Design of a new somatosensory stimulus delivery device for measuring laryngeal mechanosensory detection thresholds in humans. IEEE Trans. Biomed. Eng. 56(4), 1154-1159 (2009).
82. Hammer MJ, Barlow SM. Laryngeal somatosensory deficits in Parkinson's disease: implications for speech respiratory and phonatory control. Exp. Brain Res. 201(3), 401-409 (2010).
83. Fox C, Morrison C, Ramig L, Sapir S. Current perspectives on the Lee Silverman Voice Treatment (LSVT®). Am. J. Speech Lang. Pathol. 11, 111-123 (2002).
84. Kiran S, Larson C. Effect of duration of pitch-shifted feedback on vocal responses in patients with Parkinson's disease. J. Speech Lang. Hear. Res. 44, 975-987 (2001). (Pubitemid 34014159)
85. Liotti M, Vogel D, Sapir S, Ramig L, New P, Fox P. Abnormal auditory gating in Parkinson's disease before & after LSVT. Presented at: The Annual Meeting of the American Speech, Language and Hearing Association. Washington DC, USA, 16-19 November (2000).
86. Ramig L, Pawlas A, Countryman S. The Lee Silverman Voice Treatment (LSVT): a Practical Guide to Treating the Voice and Speech Disorders in Parkinson Disease. National Center for Voice and Speech, IA, USA (1995).
87. Ramig L, Sapir S, Countryman S, et al. Intensive voice treatment (LSVT®) for individuals with Parkinson disease: a two-year follow-up. J. Neurol. Neurosurg. Psychiatry 71, 493-498 (2001).
88. Ramig L, Sapir S, Fox C, Countryman S. Changes in vocal intensity following intensive voice treatment (LSVT®) in individuals with Parkinson disease: a comparison with untreated patients and normal age-matched controls. Mov. Disord. 16, 79-83 (2001). (Pubitemid 36041117)
89. Cunnington R, Iansek R, Bradshaw JL. Movement-related potentials in Parkinson's disease: external cues and attentional strategies. Mov. Disord. 14, 63-68 (1999). (Pubitemid 29224678)
90. Oliveira RM, Gurd JM, Nixon P, Marshall JC, Passingham RE. Micrographia in Parkinson's disease: the effect of providing external cues. J. Neurol. Neurosurg. Psychiatry. 63, 429-433 (1997). (Pubitemid 27423546)
91. Rochester L, Rafferty D, Dotchin C, Msuya O, Minde V, Walker RW. The effect of cueing therapy on single and dual-task gait in a drug naïve population of people with Parkinson's disease in northern Tanzania. Mov. Disord. 25, 906-911 (2010).
92. Bohnen NI, Kaufer DI, Hendrickson R, et al. Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and Parkinsonian dementia. J. Neuro. 253, 242-247 (2006). (Pubitemid 43255898)
93. Rowe J, Stephan KE, Friston K, Frackowiak R, Lees A, Passingham R. Attention to action in Parkinson's disease: impaired effective connectivity among frontal cortical regions. Brain. 125, 276-289 (2002). (Pubitemid 34127430)
94. Morris ME, Iansek R, Matyas TA, Summers JJ. Stride length regulation in Parkinson's disease. Normalization strategies and underlying mechanisms. Brain 119(2), 551-568 (1996).
95. Sapir S, Ramig L, Hoyt P, O'Brien C, Hoehn M. Phonatory-respiratory effort (LSVT®) vs. respiratory effort treatment for hypokinetic dysarthria: comparing speech loudness and quality before and 12 months after treatment. Folia Phoniatr. 54, 296-303 (2002).
96. Allan CM. Treatment of non-fluent speech resulting from neurological disease: treatment of dysarthria. Br. J. Disord. Comm. 5, 3-5 (1970).
97. Greene HCL. The Voice and Its Disorders. Pitman Medical, London, UK (1980).
98. Sarno MT. Speech impairment in Parkinson's disease. Arch. Phys. Med. Rehabil. 49(5), 269-275 (1968).
99. Weiner WJ, Lang AE. Movement Disorders: A Comprehensive Survey. Futura, NY, USA (1989).
100. Scott S, Caird FL. Speech therapy for Parkinson's disease. J. Neurol. Neurosurg. Psychiatry. 46, 140-144 (1983).
101. Robertson S, Thompson F. Speech therapy in Parkinson's disease: a study of efficacy and long term effects of intensive treatment. Br. J. Disord. Commun. 19, 213-224 (1984). (Pubitemid 15196677)
102. Johnson J, Pring T. Speech therapy and Parkinson's disease: a review and further data. Br. J. Disord. Comm. 125, 183-194 (1990). (Pubitemid 20271466)
103. Ramig L, Countryman S, Thompson L, Horii, Y. A comparison of two forms of intensive speech treatment for Parkinson disease. J. Speech Hear. Res. 38, 1232-1251 (1995).
104. Speech therapy in Parkinson's disease. Mov. Disord. 17(4), S163-S166 (2002).
105. Robey RR, Schultz MC. A model for conducting clinical-outcome research: an adaptation of the standard protocol for use in aphasiology. Aphasiology 12, 787-810 (1998).
106. Ramig L, Mead C, Scherer R, Horii Y, Larson K, Kohler D. Voice therapy and Parkinson's disease: a longitudinal study of efficacy. Presented at: The Clinical Dysarthria Conference. San Diego, CA, USA, 4-7 February (1988).
107. Ramig L, Dromey C. Aerodynamic mechanisms underlying treatment-related changes in vocal intensity in patients with Parkinson disease. J. Speech Hear. Res. 39, 798-807 (1996).
108. Cohen J. Statistical Power Analysis for the Behavioral Sciences (2nd Edition). Lawrence Erlbaum, NY, USA (1988).
109. Dromey C, Ramig L, Johnson A. Phonatory and articulatory changes associated with increased vocal intensity in Parkinson disease: a case study. J. Speech Hear. Res. 38, 751-763 (1995).
110. Spielman J, Borod J, Ramig L. Effects of intensive voice treatment (LSVT) on facial expressiveness in Parkinson's disease: preliminary data. Cog. Behav. Neurology 16, 177-188 (2003). (Pubitemid 37243441)
111. El-Sharkawi A, Ramig LO, Logemann JA, et al. Swallowing and voice effects of Lee Silverman Voice Treatment (LSVT®): a pilot study. J. Neurol. Neurosurg. Psychiatry 71, 31-36 (2002). (Pubitemid 34073092)
112. Dishman RK, Berthoud HR, Booth FW, et al. Neurobiology of exercise. Obesity 14(3), 345-356 (2006). (Pubitemid 46219751)
113. Dromey C, Ramig L. Intentional changes in sound pressure level and rate: their impact on measures of respiration, phonation, and articulation. J. Speech Lang. Hear. Res. 41, 1003-1018 (1998). (Pubitemid 28450229)
114. Kleinow J, Smith A, Ramig L. Speech stability in idiopathic Parkinson disease: effects of rate and loudness manipulations. J. Speech Lang. Hear. Res. 44(5), 1041-1051 (2001). (Pubitemid 34014165)
115. Ramig L, Sapir S, Baker K, et al. The 'big picture' on the role of phonation in the treatment of individuals with motor speech disorders: Or 'what's up with loud?' Presented at: The Tenth Biennial Conference on Motor Speech. San Antonio, TX, USA, 2-6 February (2000).
116. Tjaden K, Wilding GE. Rate and loudness manipulations in dysarthria: acoustic and perceptual findings. J. Speech Lang. Hear. Res. 47(4), 766-783 (2004). (Pubitemid 39129112)
117. Watson PJ, Hughes D. The relationship of vocal loudness manipulation to prosodic F0 and durational variables in healthy adults. J. Speech Lang. Hear. Res. 636-644 (2006). (Pubitemid 46940105)
118. Liotti M, Ramig LO, Vogel D, et al. Hypophonia in Parkinson's disease. Neural correlates of voice treatment revealed by PET. Neurology 60, 432-440 (2003). (Pubitemid 36188239)
119. Will L, Spielman J, Ramig L. Stimulated or trained loudness: is there a difference and does it matter? Presented at: The Conference on Motor Speech Disorders. Austin, TX, USA, 23-26 March 2006.
120. Schulman R. Articulatory dynamics of loud and normal speech. J. Acoust. Soc. Am. 85, 295-312 (1989). (Pubitemid 19041126)
121. Kleim JA, Napper RMA, Swain RA, Armstrong KE, Jones TA, Greenough WT. Selective synaptic plasticity in the cerebellar cortex of the rat following complex motor learning. Soc. Neurosci. Abstr. 20(2), 1435 (1994).
122. Narayana S, Fox PT, Zhang W, et al. Neural correlates of efficacy of voice therapy in Parkinson's disease identified by performance-correlation analysis. Hum. Brain Mapp. 31, 222-236 (2010).
123. Narayana S, Vogel D, Brown S, et al. Mechanism of action of voice therapy in Parkinson's hypophonia - a PET study. Presented at: The 11th Annual Meeting of the Organization for Human Brain Mapping. Toronto, Ontario, Canada, 12-16 June (2005).
124. Fox C, Ramig L, Ciucci M, et al. The science and practice of LSVT/LOUD: neural plasticity-principled approach to treating individuals with Parkinson disease and other neurological disorders. Semin. Speech Lang. 27, 283-299 (2006). (Pubitemid 44970749)
125. Ofer-Noy N, Dudai Y, Karni A. Skill learning in mirror reading: how repetition determines acquisition. Cog. Brain Res. 17, 507-521 (2003). (Pubitemid 36860074)
126. Tillerson J, Miller G. Forced limb-use and recovery following brain injury. Neuroscientist 8, 574-585 (2002). (Pubitemid 35379452)
127. Berardelli A, Rothwell JC, Thompson PD, Hallett M. Pathophysiology of bradykinesia in Parkinson's disease. Brain 124, 2131-2146 (2001).
128. Allen, G. Segmental timing control in speech production. J. Phon. 1, 219-237 (1973).
129. Dromey C, Ramig L. The effect of lung volume on selected phonatory and articulatory variables. J. Speech Lang. Hear. Res. 41, 491-502 (1998). (Pubitemid 28299842)
130. Gandour J, Dechongkit S, Ponglorpisit S, Khunadorn F. Speech timing at the sentence level in Thai after unilateral brain damage. Brain Lang. 46, 419-438 (1994). (Pubitemid 24110606)
131. Cookman S, Verdolini K. Interrelation of mandibular laryngeal functions. J. Voice 13, 11-24 (1999). (Pubitemid 29415822)
132. Higgins MB, Netsell R, Schulte L. Vowel-related differences in laryngeal articulatory and phonatory function. J. Speech Lang. Hear. Res. 41, 712-724 (1998). (Pubitemid 28357793)
133. Larson KK, Sapir S. Orolaryngeal reflex responses to changes in affective state. J. Speech Lang. Hear. Res. 38, 990-1000 (1995).
134. McClean MD, Tasko SM. Association of orofacial with laryngeal and respiratory motor output during speech. Exp. Brain Res. 146, 481-489 (2002).
135. Sapir S. The intrinsic pitch of vowels: theoretical, physiological, and clinical considerations. J. Voice 3, 44-51 (1989). (Pubitemid 19069014)
136. Sapir S, Larson KK. Supralaryngeal muscle activity during sustained vibrato in four sopranos: surface EMG findings. J. Voice 7, 213-218 (1993). (Pubitemid 23239715)
137. Roy N, Nissen SL, Dromey C, Sapir S. Articulatory changes in muscle tension dysphonia: evidence of vowel space expansion following manual circumlaryngeal therapy. J. Commun. Disord. 42, 124-135 (2009).
138. von Cramon D, Jürgens U. The anterior cingulate cortex and the phonatory control in monkey and man. Neurosci. Biobehav. Rev. 7, 423-425 (1983). (Pubitemid 14188328)
139. Jürgens U, Kirzinger A, von Cramon D. The effects of deep-reaching lesions in the cortical face area on phonation. A combined case report and experimental monkey study. Cortex 18, 125-130 (1982).
140. Kitchen DM, Cheney DL, Seyfarth RM. Male chacma baboons (Papio hamadryas ursinus) discriminate loud call contests between rivals of different relative ranks. Anim. Cogn. 8, 1-6 (2005). (Pubitemid 40101494)
141. Leinonen L, Laakso ML, Carlson S, Linnankoski I. Shared means and meanings in vocal expression of man and macaque. Logoped. Phoniatr. Vocol. 28, 53-61 (2003). (Pubitemid 37279375)
142. Jürgens U. Neuronal control of mammalian vocalization, with special reference to the squirrel monkey. Naturwissenschaften 85, 376-388 (1998). (Pubitemid 28402157)
143. Sapir S, Aronson AE. Aphonia after closed head injury: aetiologic considerations. Br. J. Disord. Commun. 20, 289-296 (1985). (Pubitemid 16224584)
144. McClean M, Tasko S. Association of orofacial muscle activity and movement during changes in speech rate and intensity. J. Speech Lang. Hear. Res. 46, 1387-1400 (2003). (Pubitemid 37541844)
145. Wohlert A, Hammen V. Lip muscle activity related to speech rate and loudness. J. Speech Lang. Hear. Res. 43, 1229-1239 (2000).
146. Sapir S, Ramig L, Fox C. The Lee Silverman Voice Treatment for voice, speech and other orofacial disorders in patients with Parkinson's disease. Future Neurol. 1, 563-570 (2006).
147. Jürgens U, Zwirner P. The role of the periaqueductal grey in limbic and neocortical vocal fold control. Neuroreport 7, 2921-2923 (1996). (Pubitemid 26426360)
148. Meissner I, Sapir S, Kokmen E, Stein SD. The paramedian diencephalic syndrome: a dynamic phenomenon. Stroke 18, 380-385 (1987). (Pubitemid 17059663)
149. Sapir S, Campbell C, Larson C. Effect of geniohyoid, cricothyroid and sternothyroid muscle stimulation on voice fundamental frequency of electrically elicited phonation in rhesus macaque. Laryngoscope 91, 457-468 (1981). (Pubitemid 11155291)
150. West RA, Larson CR. Neurons of the anterior mesial cortex related to faciovocal activity in the awake monkey. J. Neurophysiol. 74, 1856-1869 (1995).
151. de Swart BJ, Willemse SC, Maassen BA, Horstink MW. Improvement of voicing in patients with Parkinson's disease by speech therapy. Neurology 60(3), 498-500 (2003). (Pubitemid 36188251)
152. Liotti M, Ramig L. Improvement of voicing in patients with Parkinson's disease by speech therapy. Neurology 61(9), 1316-1317 (2003). (Pubitemid 37377574)
153. Tillerson J, Cohen AD, Philhower J, Miller GW, Zigmond MJ, Schallert T. Forced limb-use effects on the behavioral and neurochemical effects of 6-hydroxydopamine. J. Neuroscience 21, 4427-4435 (2001). (Pubitemid 32538569)
154. Tillerson J, Caudle WM, Reveron ME, Miller GW. Exercise induces behavioral recovery and attenuates neurochemical deficits in rodent models of Parkinson's disease. Neuroscience 119, 899-911 (2003). (Pubitemid 36694814)
155. Alexander GE, Crutcher MD. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci.13, 266-271 (1990). (Pubitemid 20193456)
156. Graybiel AM. The basal ganglia and chunking of action repertoires. Neurobiol. Learn. Mem. 70, 119-136 (1998). (Pubitemid 28455587)
157. Yorkston K, Spencer KA, Duffy JR. Behavioral management of respiratory/phonatory dysfunction from dysarthria: a systematic review of the evidence. J. Med. Speech Lang. Pathol. 11, xiii-xxxviii (2003). (Pubitemid 36638038)
158. Yorkston KM, Hakel M, Beukelman DR, Fager S. Evidence for effectiveness of treatment of loudness, rate, or prosody in dysarthria: a systematic review. J. Med. Speech Lang. Pathol. 15(2), xi-xxxvi (2007). (Pubitemid 47025109)
159. Halpern A, Matos C, Ramig LO, Petska J, Spielman J. LSVTC - a PDA supported speech treatment for Parkinson's disease. Presented at: The 9th International Congress of Parkinson's Disease and Movement Disorders. New Orleans, LA, USA 2-5 March (2005).
160. Ward E, Theodoros D, Murdoch B, Silburn P. Changes in maximum capacity tongue function following the Lee Silverman Voice Treatment program. J. Med. Speech Lang. Pathol. 8, 331-335 (2000).
161. Howell S, Tripoliti E, Pring T. Delivering the Lee Silverman Voice Treatment (LSVT) by web camera: a feasibility study. Int. J. Lang. Commun. Disord. 44, 287-300 (2009).
162. Tindall LR, Huebner RA, Stemple JC, Kleinert HL. Videophone-delivered voice therapy: a comparative analysis of outcomes to traditional delivery for adults with Parkinson's disease. Telemed. J. E Health 14, 1070-1077 (2008).
163. Countryman S, Ramig L. Effects of intensive voice therapy on voice deficits associated with bilateral thalamotomy in Parkinson's disease: a case study. J. Med. Speech Lang. Pathol.1, 233-250 (1993).
164. Halpern A, Spielman J, Ramig L, Down I, Gilley P. Speech Treatment for Individuals with IPD Post Deep Brain Stimulation: LSVT-DBS. Presented at: The 15th Biennial Conference on Motor Speech. Savannah, GA, USA, 3-7 March 2010 (2010).
165. Sapir S, Halpern A, Spielman J, Ramig L, Gilley P. Speech Treatment for individuals with idiopathic Parkinson's disease post DBS-STN: LSVT-DBS. Presented at: The Second International Symposium on Basal Ganglia Speech Disorders and Deep Brain Stimualtion. Aix en Provence, France, 29 June-1 July (2010).
166. Tassorelli C, Buscone S, Sandrini G, et al. The role of rehabilitation in deep brain stimulation of the subthalamic nucleus for Parkinson's disease: a pilot study. Parkinsonism Relat Disord. 15, 675-681 (2009).
167. Countryman S, Ramig L, Pawlas A. Speech and voice deficits in Parkinsonian Plus syndromes: can they be treated? J. Med. Speech Lang. Pathol. 2(3), 211-225 (1994).
168. Duncan S. Preliminary data on effects of behavioral and levodopa therapies of speech-accompanying gesture in Parkinson's disease. Presented at: The ICSLP Meeting. Denver, CO, USA, 16-20 September (2002).
169. Theodoros DG, Constantinescu G, Russell TG, et al. Treating the speech disorder in Parkinson's disease online. J. Telemed. Telecare. 12, S3, 88-91 (2006).
170. Bauer J, Mittal J, Larson C, Hain T. Vocal responses to unanticipated perturbations in voice loudness feedback: an automatic mechanism for stabilizing voice amplitude. J. Acous. Soc. Am. 119, 2363-2371 (2006).
171. Ciucci MR, Ma ST, Fox C, Kane JR, Ramig LO, Schallert T. Qualitative changes in ultrasonic vocalization in rats after unilateral dopamine depletion or haloperidol: a preliminary study. Behav. Brain Res. 182(2) 284-289 (2007). (Pubitemid 47411464)
172. Miller JE, Burkett ZD, White SA. Birdsong as a model system for early detection of Parkinson disease. Presented at: Annual Society for Neuroscience Meeting, Chicago, IL, USA, 21-27 October (2009).
173. Fox CM, Farley BG, Ramig LO, McFarland D. An integrated speech and physical therapy approach for Parkinson disease: Training BIG and LOUD. Mov.
174. Constantinescu GA, Theodoros DG, Russell TG, Ward EC, Wilson SJ, Wootton R. Home-based speech treatment for Parkinson's disease delivered remotely: a case report. J. Telemed. Telecare 16, 100-104 (2010).
175. Ramig L, Countryman S, O'Brien C, Hoehn M, Thompson L. Intensive speech treatment for individuals with Parkinson's disease: short- and long-term comparison of two techniques. Am. Acad. Neurol. 47, 1496-1504 (1996). (Pubitemid 26422543)
176. Till JA, Yorkston KM, Beukelman R. Motor Speech Disorders: Advances in Assessment and Treatment. Paul H Brooks, Baltimore, MD, USA (1994).